The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: Outcomes of a drug and disease model

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 1, 2010, Pages 405-412

  Holz, Frank G ^a   Korobelnik, Jean François ^b   Lanzetta, Paolo ^c   Mitchell, Paul ^d   Schmidt Erfurth, Ursula ^e   Wolf, Sebastian ^f   Markabi, Sabri ^g,h   Schmidli, Heinz ^g   Weichselberger, Andreas ^g  

^a UNIVERSITY OF BONN   (Germany)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF UDINE   (Italy)

^d UNIVERSITY OF SYDNEY   (Australia)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f UNIVERSITY OF BERN   (Switzerland)

^g NOVARTIS PHARMA AG   (Switzerland)

^h ALCON RESEARCH LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VERTEPORFIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MODEL; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; IC 50; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PHASE 3 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; TREATMENT OUTCOME; VISUAL ACUITY; BIOLOGICAL MODEL; DISEASE COURSE; DRUG ANTAGONISM; INJECTION; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA MACULA DEGENERATION; RETREATMENT; VITREOUS BODY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DISEASE PROGRESSION; FEMALE; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; MODELS, BIOLOGICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETREATMENT; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 75749133304     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3813     Document Type: Article

References (43)

1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
3. Regillo CD, Brown DM, Abraham P, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145(2):239-248.
4. Chong V. Exploratory analysis of characteristics predicting response to ranibizumab at 12 months in the PIER study of ranibizumab. Abstract presented at the 7th EURETINA Congress, Monte Carlo, Monaco, May 17-20, 2007.
5. Reitman ML, Schadt EE. Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest. 2007;117(5):1226-1229.
6. McLaren NC, Moroi SE. Clinical implications of pharmacogenetics for glaucoma therapeutics. Pharmacogenomics J. 2003;3(4):197-201.
7. Baird PN, Richardson AJ, Robman LD, et al. Apolipoprotein (APOE) gene is associated with progression of age-related macular degeneration (AMD). Hum Mutat. 2006;27(4):337-342.
8. Seddon JM, Francis PJ, George S, Schultz DW, Rosner B, Klein ML. Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. JAMA. 2007;297(16):1793-1800.
9. Nicolas CM, Robman LD, Tikellis G, et al. Iris colour, ethnic origin and progression of age-related macular degeneration. Clin Exp Ophthalmol. 2003;31(6):465-469.
10. Churchill AJ, Carter JG, Lovell HC, et al. VEGF polymorphisms are associated with neovascular age-related macular degeneration. Hum Mol Genet. 2006;15(19):2955-2961.
11. Wakusawa R, Abe T, Sato H, et al. Expression of vasohibin, an antiangiogenic factor, in human choroidal neovascular membranes. Am J Ophthalmol. 2008;146(2):235-243.
12. Grisanti S, Tatar O. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res. 2008;27(4):372-390.
13. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008;27(4):331-371.
14. Jonas JB, Neumaier M. Vascular endothelial growth factor and basic fibroblast growth factor in exudative age-related macular degeneration and diffuse diabetic macular edema. Ophthalmic Res. 2007;39(3):139-142.
15. Chang MA, Bressler SB, Munoz B, West SK. Racial differences and other risk factors for incidence and progression of age-related macular degeneration: Salisbury Eye Evaluation (SEE) Project. Invest Ophthalmol Vis Sci. 2008;49(6):2395-2402.
16. Klein R, Knudtson MD, Cruickshanks KJ, Klein BE. Further observations on the association between smoking and the long-term incidence and progression of age-related macular degeneration: the Beaver Dam Eye Study. Arch Ophthalmol. 2008;126(1):115-121.
17. Seddon JM, Cote J, Rosner B. Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake. Arch Ophthalmol. 2003;121(12):1728-1737.
18. Chiu CJ, Milton RC, Gensler G, Taylor A. Association between dietary glycemic index and age-related macular degeneration in nondiabetic participants in the Age-Related Eye Disease Study. Am J Clin Nutr. 2007;86(1):180-188.
19. Robman L, Vu H, Hodge A, et al. Dietary lutein, zeaxanthin, and fats and the progression of age-related macular degeneration. Can J Ophthalmol. 2007;42(5):720-726.
20. Evans JR. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. 2006;(2):CD000254.
21. Chong EW, Kreis AJ, Wong TY, Simpson JA, Guymer RH. Dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: a systematic review and metaanalysis. Arch Ophthalmol. 2008;126(6):826-833.
22. Chiu CJ, Milton RC, Klein R, Gensler G, Taylor A. Dietary carbohydrate and the progression of age-related macular degeneration: a prospective study from the Age-Related Eye Disease Study. Am J Clin Nutr. 2007;86(4):1210-1218.
23. Kaushik S, Wang JJ, Flood V, et al. Dietary glycemic index and the risk of age-related macular degeneration. Am J Clin Nutr. 2008;88(4):1104-1110.
24. Cugati S, Mitchell P, Rochtchina E, Tan AG, Smith W, Wang JJ. Cataract surgery and the 10-year incidence of age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology. 2006;113(11):2020-2025.
25. Chakravarthy U, Augood C, Bentham GC, et al. Cigarette smoking and age-related macular degeneration in the EUREYE Study. Ophthalmology. 2007;114(6):1157-1163.
26. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114(2):246-252.
27. Wang JJ, Foran S, Smith W, Mitchell P. Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: the Blue Mountains Eye Study cohort. Arch Ophthalmol. 2003;121(5):658-663.
28. Parker C, Muston D, Melia J, Moss S, Dearnaley D. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer. 2006;94(10):1361-1368.
29. Sanga S, Sinek JP, Frieboes HB, Ferrari M, Fruehauf JP, Cristini V. Mathematical modeling of cancer progression and response to chemotherapy. Expert Rev Anticancer Ther. 2006;6(10):1361-1376.
30. Barrett JS, Gupta M, Mondick JT. Model-based drug development applied to oncology. Expert Opin Drug Discov. 2007;2(2):185-209.
31. Post TM, Freijer JI, DeJongh J, Danhof M. Disease system analysis: basic disease progression models in degenerative disease. Pharm Res. 2005;22(7):1038-1049.
32. Chan PL, Nutt JG, Holford NH. Modeling the short-and longduration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease. J Pharmacokinet Pharmacodyn. 2004;31(3):243-268.
33. Lockwood P, Ewy W, Hermann D, Holford N. Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease. Pharm Res. 2006;23(9):2050-2059.
34. Chan PL, Nutt JG, Holford NH. Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation. Pharm Res. 2007;24(4):791-802.
35. Wu SY, Sainfort F, Tomar RH, et al. Development and application of a model to estimate the impact of type 1 diabetes on healthrelated quality of life. Diabetes Care. 1998;21(5):725-731.
36. De Ridder F. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development. Basic Clin Pharmacol Toxicol. 2005;96(3):235-241.
37. Novartis Pharma AG. Summary of Product Characteristics: Lucentis. Basel, Switzerland; 2007.
38. NCT00056836. A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration. Available at http://www.clinicaltrials.gov/ct2/show/NCT00056836. Accessed January 7, 2009.
39. NCT00061594. A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00061594. Accessed January 7, 2009.
40. NCT00090623. A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD). Available at http://www-.clinicaltrials.gov/ct2/show/NCT00090623. Accessed January 7, 2009.
41. Xu L, Jumbe N, Eppler S, Lu J, Damico L, Joshi A. Population pharmacokinetics of ranibizumab in patients with age-related macular degeneration. Abstract presented at the AAPS meeting, San Antonio, TX, October 2-November 29, 2006.
42. Gabrielsson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis, Concepts and Applications. 4th ed. Florida: Baco Raton; 2007.
43. NCT00331864. SUSTAIN: Study of Ranibizumab in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Available at http://www.clinicaltrials.gov/ct2/show/NCT00331864. Accessed January 15, 2009.